InSilico Medicine Cayman TopCo valuation
$58.60Change from previous close: +2.81%Absolute change: +$1.60
Valuation
The average price target of 8 analysts is $81.40.
Data as of October 4, 2026
Valuation multiples
- Market cap
- $33.34B
- Enterprise value
- $32.6B
- Forward P/E
- 33.1
- Price/book
- 7.73
- Price/sales
- 246.8
- EV/EBITDA
- -5,113.4
- EV/revenue
- 241.4
Profitability and growth
- Gross margin
- 87.9%
- Operating margin
- 26.6%
- Net margin
- -220.3%
- ROA
- -1.4%
- Revenue growth (year over year)
- 287.2%
Financial health
- Total cash
- $584.82M
- Total debt
- $19.66M
- Debt/equity
- 0.04
- Current ratio
- 8.71
- Quick ratio
- 8.65
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $81.40
- Median price target
- $79.09
- High price target
- $100.03
- Low price target
- $71.00
- Analysts with a price target
- 8
- Consensus
- Strong buy
- Forward EPS
- $1.74
- EPS estimate, current year
- $0.08
Shares and trading
- Average volume
- 16.24M
- Shares outstanding
- 578.89M
- Float
- 502.94M
- Institutional ownership
- 28.2%
- Insider ownership
- 7.8%